At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 329 enrolled
Drug / intervention
Baricitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7
In Brief
A Phase 3 clinical trial evaluating Baricitinib, Topical corticosteroid, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 329 participants across 68 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesArgentina, Australia, Austria, Germany, Italy, Japan, Poland, South Korea, Spain, Taiwan
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartNov 16, 2018
Primary CompletionJul 29, 2019
Study CompletionAug 22, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.7 years ago
Interventions
Baricitinibdrug
Administered orally.
Topical corticosteroiddrug
Administered as standard-of-care.
Placebodrug
Administered orally.